A Randomized Phase II Multicenter Study to Assess the Tolerability and Efficacy of the Addition of Midostaurin to 10-day Decitabine Treatment in Unfit Adult Acute Myeloid Leukemia and High Risk Myelodysplasia Patients
Latest Information Update: 18 Mar 2025
At a glance
- Drugs Midostaurin (Primary) ; Decitabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms HO155; HOVON 155 AML; HOVON155
Most Recent Events
- 05 Jan 2023 Planned End Date changed from 1 Mar 2026 to 1 Nov 2026.
- 29 Dec 2021 Planned primary completion date changed from 1 Oct 2021 to 30 Jun 2022.
- 29 Dec 2021 Status changed from recruiting to active, no longer recruiting.